One of the most important characteristics of a hemp extract—beyond its formulation and the purity of its ingredients—is determining the correct dose for an individual. Recent research has shown that "more is better" is not always true. The correct dosing of hemp extracts depends to a large extent on the type of extract being considered.
Click on any of the below WINGS products to see their dosage calculator:
The unofficial mantra of consumers and wellness caregivers attempting to accurately dose hemp tinctures has become "start low, go slow.” If consumption volumes and resulting efficacy are carefully recorded in a journal, consumers will find their personal "efficacy bell curve" or “sweet spot.”
This efficacy bell curve is illustrated when a patient continues to increase dosing levels and begins to notice a drop off, or decrease, in positive efficacy. This is the signal that dosing needs to decrease to the level where maximum efficacy is experienced.
The following steps will help consumers find their personal dose:
Metabolic changes from aging, injury, seasonal shifts, and environmental stressors may require a repeat of this dosing process in the future. This is especially true of children due to their rapid growth rate.
As its name implies, microdosing is an approach to the consumption of herbal remedies involving very small doses, often administered throughout the day. Most typically we dose twice a day, though in some instances it can be beneficial for the user to dose more frequently. The idea behind microdosing is to attempt keeping the level of cannabinoids in the body as even as possible throughout the day, avoiding waxing and waning. take the smallest dose required at that time and continue to dose throughout the day. This might be desired if the consumer has an unusually high metabolism
An effective microdose for one person may be inappropriate for another based on factors such as genetic predisposition, body weight, pharmaceutical drugs being consumed, existing conditions, and environmental factors, and stressors.
Social media and online resources have allowed consumers from around the world to share the results of their dosing experimentation. This is especially true in particular patient communities where specific formulations and accurate dosing it critical to gain maximum efficacy. In many cases, efficacy can be objectively measured in terms of, for example, a reduction in number of seizures. In other use cases, efficacy is more obfuscated, such as in subjective reports of pain levels.
Jai Anstis, a 3-year-old boy in New Zealand, reported the greatest efficacy for West Syndrome with epileptic encephalopathy and autism spectrum disorder after a significant reduction of dose when changing from Tilray's 98% purified CBD extract to WINGS. Maximum seizure relief was found after reducing dosing from 240 mg per day of the CBD isolate to only 10 mg of the WINGS hemp tincture, Amazing Grace.
While this evidence is purely anecdotal and should not be misinterpreted as clinically valid, a reduction of 2,400% is significant and exemplifies the difference between an isolate and a full-spectrum product. This transition and adjustment in dose allowed the user to gain the greatest relief while also dramatically reducing the cost of their wellness supplementation and increasing the efficacy of cannabinoids in his body due to the very low dose. Additionally, many other symptoms were abated due to the variety of cannabinoids and terpenes within WINGS that wouldn't otherwise be present with an isolated CBD.
Much research has been conducted into the dosing characteristics of CBD. A review of this research is helpful to fully understand the dynamics of CBD titration and avoid the pitfalls of too weak—or too potent—a dose.
A 2015 research study entitled "Overcoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol" that was published in the journal Pharmacology & Pharmacy found full-spectrum hemp extracts to be more potent and feature greater efficacy than a CBD isolate.
Researchers reported, "Our findings that CBD in the presence of other plant constituents improve the dose-response are supported by some recent reports showing that CBD in a standardized cannabis sativa extract is more potent or efficacious than pure CBD."
A 2012 study entitled "Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia" and published in the journal Translational Psychiatry found that 800 mg of CBD was as effective as standard pharmaceutical treatments—but lacked the negative side effects often delivered by antipsychotic drugs.
The researchers also discovered that CBD "moderately inhibits the degradation of the endocannabinoid anandamide," giving more credence to the entourage effect theory.
These statements have not been evaluated by the Food and Drug Administration for safety or efficacy. This product is not intended to diagnose, treat, cure or prevent any disease.